HER2 in situ hybridization in breast cancer: Clinical implications of polysomy 17 and genetic heterogeneity

Modern Pathology

Volumn 27, Issue 1, 2014, Pages 4-18

  Hanna, Wedad M ^a   Rüschoff, Josef ^b   Bilous, Michael ^c   Coudry, Renata A ^d   Dowsett, Mitch ^e   Osamura, Robert Y ^f   Penault Llorca, Frédérique ^g   Van De Vijver, Marc ^h   Viale, Giuseppe ⁱ  

^a UNIVERSITY OF TORONTO   (Canada)

^b Institute of Pathology Nordhessen   (Germany)

^c Bella Vista   (Australia)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f International University of Health and Welfare Mita Hospital   (Japan)

^g CENTRE JEAN PERRIN   (France)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁱ UNIVERSITY OF MILAN   (Italy)

Author keywords

breast cancer; chromosome 17; genetic heterogeneity; HER2 testing; in situ hybridization; polysomy

Indexed keywords

CEP17 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER PROGNOSIS; CENTROMERE; CHROMOSOME ABERRATION; CLINICAL PRACTICE; CONSENSUS; DISOMY; FEMALE; GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC ALGORITHM; GENETIC HETEROGENEITY; HER2 GENE; HUMAN; IN SITU HYBRIDIZATION; METHODOLOGY; POLYSOMY 17; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CENTROMERE; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IN SITU HYBRIDIZATION; INDIVIDUALIZED MEDICINE; PATIENT SELECTION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2;

EID: 84891747133     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.103     Document Type: Review

References (89)

1. Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989;4: 362-366.
2. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145. (Pubitemid 350003059)
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182. (Pubitemid 17231334)
4. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-2904. (Pubitemid 27330017)
5. Kallioniemi OP, Holli K, Visakorpi T, et al. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991;49:650-655.
6. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726. (Pubitemid 34111379)
7. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-4274. (Pubitemid 46207001)
8. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820. (Pubitemid 43290919)
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353: 1659-1672. (Pubitemid 41464705)
10. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: 1673-1684. (Pubitemid 41464706)
11. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792. (Pubitemid 32222155)
12. Smith I, Procter M, Gelber RD, et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36. (Pubitemid 46039831)
13. Boekhout AH, Beijnen JH, Schellens JH. Trastuzumab. Oncologist 2011;16:800-810.
14. Banerjee S, Smith IE. Management of small HER2-positive breast cancers. Lancet Oncol 2010;11: 1193-1199.
15. Jackisch C. HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncologist 2006;11(Suppl 1):34-41.
16. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer, Vol 3, 2012, pp 1-176.
17. Tse CH, Hwang HC, Goldstein LC, et al. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. J Clin Oncol 2011;29:4168-4174.
18. Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol 2011;29:e458.
19. Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009;27:1323-1333.
20. Viale G. Controversies in testing for HER2. ASCO Educ Book 2011;3-7.
21. Albertson DG. Gene amplification in cancer. Trends Genet 2006;22:447-455. (Pubitemid 44093770)
22. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199:418-423. (Pubitemid 36411217)
23. Reinholz MM, Bruzek AK, Visscher DW, et al. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol 2009;10:267-277.
24. Dal Lago L, Durbecq V, Desmedt C, et al. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 2006;5:2572-2579. (Pubitemid 44650922)
25. Vranic S, Teruya B, Repertinger S, et al. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 2011;117:48-53.
26. Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19: 2714-2721. (Pubitemid 32441377)
27. Schmidt C. How do you tell whether a breast cancer is HER2 positive Ongoing studies keep debate in high gear. J Natl Cancer Inst 2011;103:87-89.
28. Murthy SS, Sandhya DG, Ahmed F, et al. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center. Indian J Pathol Microbiol 2011;54:532-538.
29. Ma Y, Lespagnard L, Durbecq V, et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 2005;11: 4393-4399. (Pubitemid 40825629)
30. Bose S, Mohammed M, Shintaku P, Rao PN. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy. Breast J 2001;7:337-344. (Pubitemid 33101639)
31. Cuadros M, Cano C, Lopez FJ, et al. HER2 status in breast cancer: experience of a Spanish National Reference Centre. Clin Transl Oncol 2011;13:335-340.
32. Downs-Kelly E, Yoder BJ, Stoler M, et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol 2005;29:1221-1227. (Pubitemid 41232996)
33. Hajduch M, Trojanec R, Bouchalova K, et al. Chromosome 17 polysomy and Her-2/neu status in metastatic breast cancer patients indicated to trastuzumab therapy. J Clin Oncol 2005;23(16 Suppl):abstract 9584.
34. Hofmann M, Stoss O, Gaiser T, et al. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol 2008;61:89-94. (Pubitemid 351158232)
35. Hyun CL, Lee HE, Kim KS, et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol 2008;61:317-321. (Pubitemid 351354237)
36. Kokate P, Sawaimoon S, Bhatia S, Mandava S. Evaluation of genetic status of HER-2/neu and aneusomy 17 by fluorescence in situ hybridization and comparison with immunohistochemistry assay from Indian breast cancer patients. Genet Test Mol Biomarkers 2012;16:239-245.
37. Krishnamurti U, Hammers JL, Atem FD, et al. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Mod Pathol 2009;22:1044-1048.
38. Merola R, Mottolese M, Orlandi G, et al. Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2\+ in immunohistochemical analysis. Eur J Cancer 2006;42:1501-1506. (Pubitemid 43903166)
39. Mezzelani A, Alasio L, Bartoli C, et al. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer 1999;80:519-525. (Pubitemid 29213209)
40. Ö hlschlegel C, Zahel K, Kradolfer D, et al. HER2 genetic heterogeneity in breast carcinoma. J Clin Pathol 2011;64:1112-1116.
41. Salido M, Tusquets I, Corominas JM, et al. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res 2005;7:R267-R273.
42. Takehisa M, Sasa M, Bando Y, et al. Chromosomal aneusomy (chr 1, 11, 17) detected by fluorescence in situ hybridization may be a prognostic factor in breast cancer. Anticancer Res 2007;27:1073-1078. (Pubitemid 46587025)
43. Torrisi R, Rotmensz N, Bagnardi V, et al. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 2007;43:2339-2344. (Pubitemid 47625971)
44. Tsukamoto F, Miyoshi Y, Egawa C, et al. Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization. Cancer 2001;93:165-170. (Pubitemid 32322173)
45. Tubbs RR, Hicks DG, Cook J, et al. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol 2007;16:207-210. (Pubitemid 350196977)
46. Vanden Bempt I, Van LP, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 2008;26:4869-4874.
47. Varshney D, Zhou YY, Geller SA, Alsabeh R. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol 2004;121:70-77. (Pubitemid 38090156)
48. Wang S, Hossein SM, Frenkel EP, et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol 2002;15:137-145. (Pubitemid 34171323)
49. Watters AD, Going JJ, Cooke TG, Bartlett JM. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 2003;77:109-114. (Pubitemid 36197611)
50. Zaczek A, Markiewicz A, Supernat A, et al. Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer. Pathol Oncol Res 2012;18:885-894.
51. Zhu X, Lu Y, Lu H, et al. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer. Hum Pathol 2011;42: 1499-1504.
52. Petroni S, Addati T, Mattioli E, et al. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer Arch Pathol Lab Med 2012;136:993-1000.
53. Lal P, Salazar PA, Ladanyi M, et al. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn 2003;5:155-159. (Pubitemid 36974726)
54. Sahoo R, Babu VC, Harini VV, et al. Her-2/neu overexpression due to polysomy 17 in breast cancer: molecular testing to guide therapeutic options. Onkologie 2011;34:356-360.
55. Kaufman PA, Broadwater G, Lezon-Geyda LG. CALGB 150002: correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2\+ and HER2-metastatic breast cancer (MBC). J Clin Oncol 2007;25(18 Suppl):abstract 1009.
56. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26: 1642-1649.
57. Downey L, Livingston RB, Koehler M, et al. Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin Cancer Res 2010;16: 1281-1288.
58. Dowsett M, Procter M, McCaskill-Stevens W, et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol 2009;27:2962-2969.
59. Orlando L, Del CB, Gandini S, et al. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Breast 2008;17: 506-511.
60. Moelans CB, de Weger RA, van Diest PJ. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat 2010;120:1-7.
61. Troxell ML, Bangs CD, Lawce HJ, et al. Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus. Am J Clin Pathol 2006;126:709-716. (Pubitemid 44707621)
62. Marchiò C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009;219:16-24.
63. Yeh IT, Martin MA, Robetorye RS, et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 2009;22:1169-1175.
64. Viale G. Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer. J Pathol 2009;219:1-2.
65. Moelans CB, Reis-Filho JS, van Diest PJ. Implications of rarity of chromosome 17 polysomy in breast cancer. Lancet Oncol 2011;12:1087-1089.
66. Zabaglo L, Stoss O, Rueschoff J, et al. Impact of HER2 staining intensity on prognosis and treatment benefit of adjuvant trastuzumab given after chemotherapy: the HERA Trial Experience. Cancer Res 2010;70 (24 Suppl):abstract PD10-01.
67. Dekker TJ, Borg ST, Hooijer GK, et al. Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Res 2012;14:R93.
68. Bartlett JM, Campbell FM, Mallon EA. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined Am J Clin Pathol 2008;130:920-926.
69. Egervari K, Kosa C, Szollosi Z. Impact of chromosome 17 centromere region assessment on HER2 status reported in breast cancer. Pathol Res Pract 2011;207: 468-471.
70. Gunn S, Yeh IT, Lytvak I, et al. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity. BMC Cancer 2010;10:396.
71. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366: 883-892.
72. Hanna W, Nofech-Mozes S, Kahn HJ. Intratumoral heterogeneity of HER2/neu in breast cancer-a rare event. Breast J 2007;13:122-129. (Pubitemid 46280606)
73. Bernasconi B, Chiaravalli AM, Finzi G, et al. Genetic heterogeneity in HER2 testing may influence therapy eligibility. Breast Cancer Res Treat 2012;133: 161-168.
74. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 2009;133:611-612.
75. Brunelli M, Manfrin E, Martignoni G, et al. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol 2009;131:678-682.
76. Lewis JT, Ketterling RP, Halling KC, et al. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2\+) HER-2 immunostaining. Am J Clin Pathol 2005;124:273-281. (Pubitemid 41060140)
77. Albarracin C, Edgerton ME, Gilcrease MZ, et al. Is it too soon to start reporting HER2 genetic heterogeneity Arch Pathol Lab Med 2010;134:162-163.
78. Hsu CY, Li AF, Yang CF, Ho DM. Proposal of modification for the definition of genetic heterogeneity in HER2 testing in breast cancer. Arch Pathol Lab Med 2010;134:162.
79. Chang MC, Malowany JI, Mazurkiewicz J, et al. 'Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: a study of 2,522 cases. Mod Pathol 2012;25:683-688.
80. Bartlett JM, Starczynski J, Atkey N, et al. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J Clin Pathol 2011;64: 649-653.
81. Starczynski J, Atkey N, Connelly Y, et al. HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. Am J Clin Pathol 2012;137:595-605.
82. Allison KH, Dintzis SM, Schmidt RA. Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity. Am J Clin Pathol 2011;136:864-871.
83. Bartlett AI, Starcyznski J, Robson T, et al. Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am J Clin Pathol 2011;136:266-274.
84. Seol H, Lee HJ, Choi Y, et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol 2012;25: 938-948.
85. Perez EA, Dueck AC, McCullough AE, et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst 2012;104:159-162.
86. Valent A, Delaloge S, Ferchiou M, et al. Genetic heterogeneity of amplification status in breast invasive carcinoma with 2\+ HER2 immunostaining: What Can We Learn Cancer Res 2011;71(24 Suppl):abstract P3-05-07.
87. Matthiesen SH, Hansen CM. Fast and non-toxic in situ hybridization without blocking of repetitive sequences. PLoS One 2012;7:e40675.
88. Nitta H, Kelly BD, Padilla M, et al. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalinfixed, paraffin-embedded breast cancer tissue sections. Diagn Pathol 2012;7:60.
89. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14:320-368.